National Biotechnology Initiative Act of 2025
- Sponsor
- Sen. Young, Todd [R-IN]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Mar 19, 2026
Bottom line
The bill aims to centralize and accelerate federal strategy and investment in biotechnology to secure U.S. leadership in this critical emerging field.
What it actually does
This bill establishes the National Biotechnology Initiative, a comprehensive federal effort to advance biotechnology for national security, economic productivity, and global competitiveness. It creates a National Biotechnology Coordination Office within the Executive Office of the President and an Interagency Committee to oversee and coordinate activities across more than a dozen federal departments and agencies. The Initiative mandates specific actions in areas such as research and development, data management, regulatory streamlining, workforce development, and international partnerships.
Proponents argue
Supporters argue that a coordinated national strategy is essential to prevent fragmented federal efforts, accelerate scientific understanding and technological innovation, and ensure the United States remains globally competitive in biotechnology. They emphasize the importance of this initiative for national security, economic growth, and addressing societal challenges through advancements in human health, agriculture, and energy.
Opponents contend
No explicit opposition is detailed within the bill text. However, potential critics might raise concerns about the expansion of federal bureaucracy, the overall cost of the initiative, or the potential for an EOP office to overstep or duplicate the roles of existing agencies, possibly stifling private sector innovation through excessive government involvement.
The bill is relatively concise and well-structured, making it accessible for an informed reader to understand its core provisions and implications within a reasonable timeframe.
Section 3
Authorization of the National Biotechnology Initiative
This section formally establishes the National Biotechnology Initiative, mandating the President to implement it through the Executive Office of the President. It designates 14 specific federal departments and agencies, including Defense, Health and Human Services, Energy, and the National Science Foundation, as initial participants, with provisions for others to join. The Initiative's broad activities include creating a national strategy, addressing national security implications, supporting R&D, managing biological data, facilitating commercialization, streamlining regulations, and developing a domestic workforce.
Supporters argue
Supporters argue that formalizing and coordinating federal efforts under a national initiative is crucial for the United States to maintain its leadership in biotechnology, ensuring a unified approach to a strategically vital sector for both economic prosperity and national defense.
Critics contend
No specific opposition is typically raised against the general concept of a national initiative for a strategic technology, though concerns might arise regarding its scope or the potential for bureaucratic bloat.
Tradeoffs
The bill seeks to balance comprehensive federal coordination with the need for individual agency autonomy and specialized expertise, aiming to avoid both fragmented efforts and excessive centralization.
Section 4(a)
Establishment of the Interagency Committee
This provision requires the President to designate an interagency committee within 180 days of enactment to coordinate the Initiative's activities. The committee will comprise Assistant Secretary-level members from each participating agency, ensuring high-level representation. It will have three co-chairpersons, one being the Director of the National Biotechnology Coordination Office and two selected from among the members, serving staggered two-year terms to ensure continuity.
Section 4(b)
Establishment of the National Biotechnology Coordination Office
This section mandates the establishment of a National Biotechnology Coordination Office within the Executive Office of the President, along with the appointment of its Director, who will serve as the principal advisor to the President for biotechnology. The Office is tasked with extensive functions, including overseeing planning and coordination, assessing national security implications, coordinating R&D, managing biological data, facilitating commercialization, streamlining regulations, addressing biosafety and biosecurity, developing the workforce, promoting bioliteracy, and fostering international partnerships. The Office is authorized to advise OMB on agency spending to avoid duplication and can convene experts.
Section 4(b)(3)(F)
Regulatory Streamlining for Biotechnology Products
This function directs the National Biotechnology Coordination Office to coordinate the easing of regulatory burdens for biotechnology products that are well-understood by regulators, including those that could occur naturally or be developed conventionally. It mandates negotiating interagency agreements to describe clear regulatory pathways, providing information on timelines, decision points, data requirements, and agency hand-offs. The Office must also provide regular status updates to OMB and, jointly with the Interagency Committee, develop and make public a plan for regulatory streamlining within one year.
Section 4(b)(4)
Funding and Administrative Support for the Office
This section authorizes specific appropriations to the Director of the National Science Foundation (NSF) to provide administrative support for the National Biotechnology Coordination Office. This support includes appointing and compensating Office employees (such as deputy directors and experts), fixing their compensation, detailing employees, and covering other operational costs like physical space and overhead. The authorized amounts are $22,000,000 for fiscal year 2026, $35,000,000 for fiscal year 2027, and $25,000,000 for each of fiscal years 2028 through 2030.
Section 4(e)
Development of a National Biotechnology Strategy
This section mandates that the Director of the National Biotechnology Coordination Office and the Interagency Committee jointly develop and make public a comprehensive national strategy for biotechnology every five years, with the first due two years after enactment. This strategy must outline actions, goals, and priorities for the Initiative, including how agencies will integrate biotechnology, identify unfunded priorities with estimated budgets, recommend legislative actions, inventory federal biological data databases, and assess U.S. competitiveness in biotechnology relative to peer countries.
Section 6
Mandated Activities for Participating Agencies
This section details specific activities that each participating federal agency must conduct or support, consistent with their mission and in coordination with the National Biotechnology Coordination Office. These activities are extensive, covering planning and coordination (e.g., designating liaisons, implementing national strategy), national security (e.g., analyzing threats, mitigating supply chain risks), research and development (e.g., sustained support, instrumentation development), data and databases (e.g., curating data, developing standards), product commercialization (e.g., utilizing existing programs, supporting testbeds), regulatory streamlining (e.g., easing burden, establishing clear pathways), biosafety and biosecurity (e.g., developing strategies, outreach), workforce development (e.g., education, training), bioliteracy (e.g., plain-language materials), and international partnerships (e.g., engagement strategies, data-sharing agreements).
The Director of the National Biotechnology Coordination Office is authorized to advise the Director of the Office of Management and Budget (OMB) for the purposes of tracking and adjusting agency spending relating to biotechnology, including to ensure that Federal efforts are complementary and not duplicative.
Section 4(b)(2)(C)(i)
Why it matters:This is standard legislative practice for detailing specific powers of a newly created position, particularly those related to interagency coordination and fiscal oversight.
Case for: Proponents argue this is crucial for efficient use of taxpayer money, preventing redundant research or initiatives across numerous federal agencies involved in biotechnology, and ensuring strategic allocation of resources.
Case against: Critics might argue that giving an EOP director influence over agency budgets could centralize too much power and potentially override agency-specific priorities or expertise, leading to less effective resource allocation in specialized areas.
Estimated impact: Potentially significant impact on federal biotechnology spending, ensuring strategic allocation of billions of dollars over time by preventing duplication and promoting synergy.
In the event that the National Biotechnology Coordination Office and the Interagency Committee cannot reach timely agreement on a clear regulatory pathway for a product type, the Director of the Office of Management and Budget (OMB) shall identify overlaps, negotiate an interagency agreement for a clear regulatory pathway, and recommend rulemaking or guidance changes as needed.
Section 4(b)(5)
Why it matters:This is a standard legislative mechanism to provide an escalation path for resolving interagency disputes, ensuring that the goal of regulatory streamlining is ultimately met even in the face of internal disagreements.
Case for: Supporters argue this provides a critical backstop to ensure regulatory streamlining actually happens, preventing agencies from stalling progress due to disagreements and ensuring that the biotechnology industry receives the clarity it needs.
Case against: Critics might contend that this gives OMB too much power over the technical expertise of regulatory agencies, potentially leading to less robust or well-informed regulatory decisions if political expediency overrides scientific caution.
Estimated impact: Could significantly impact the regulatory landscape for specific biotechnology products, potentially accelerating market entry for some innovations or altering the regulatory burden for others.
The National Biotechnology Coordination Office shall wind down its activities 20 years after the date of the enactment of this Act, transitioning to serving as an executive secretariat for the Initiative, with authorities, requirements, resources, personnel, and obligations transferred to the Interagency Committee or other federal elements.
Section 4(b)(6)
Why it matters:This is a common legislative practice to ensure that new offices or initiatives are not permanent unless explicitly reauthorized, providing a sunset clause that addresses concerns about perpetual bureaucracy.
Case for: Proponents argue this ensures accountability and prevents the creation of a permanent bureaucracy, allowing for future reassessment of the Initiative's needs and structure based on evolving technological and policy landscapes.
Case against: Critics might argue that a 20-year sunset could create uncertainty for long-term planning and investment in biotechnology, potentially hindering sustained strategic efforts and the ability to attract and retain top talent for a temporary office.
Estimated impact: Shapes the long-term institutional structure of federal biotechnology coordination, influencing its stability, adaptability, and perceived permanence over decades.